Pfizer Inc. (PFE)
Pfizer: The AI Hedge That Pays You To Stay Defensive
Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious stance in volatile markets. PFE offers an attractive opportunity to offset AI-related risks within a broader portfolio context.
Pfizer: The Post-Pandemic Turnaround Is Already Underway
Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/acquired products, especially from Seagen, are driving robust 20%+ growth. Seagen's acquisition is reshaping PFE's growth, with Padcev leading oncology momentum and a strong cost savings program underway.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait
McDonald's (NYSE:MCD | MCD Price Prediction) versus Pfizer (NYSE:PFE): which one deserves a place in a retirement-focused portfolio right now?
‘It Kills Me to Say That': Cramer Won't Recommend Pfizer, Even With Its 7% Dividend
Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it.
3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)
Income investors watching the calendar have a narrow window this week. Three of the market's most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day.
Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat
I keep buying Pfizer (NYSE:PFE | PFE Price Prediction) every time my brokerage cash builds up, and I am not slowing down.
This 7% Yielding Healthcare Powerhouse Belongs in Retirees' Portfolios
Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE | PFE Price Prediction).
